Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07087431 · ClinicalTrials.gov registry record · NA
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
A NA study of Coronary Artery Disease, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT07087431: Recruiting NA study of Coronary Artery Disease, sponsored by Massachusetts General Hospital.
NCT07087431 is a NA study of Coronary Artery Disease that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 500 participants, below the 1,285-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07087431, a NA study of Coronary Artery Disease, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.
Primary Outcome
The primary outcome is the change in low-density lipoprotein cholesterol (LDL-C) from baseline to 12 months. LDL-C values will be obtained from clinical measurements recorded in the electronic health record. The analysis will compare the change in LDL-C between participants randomized to immediate disclosure versus deferred disclosure of CAD PRS results.
Conditions Studied
Interventions
- BEHAVIORAL Immediate disclosure of CAD PRS results
- BEHAVIORAL Deferred Disclosure of CAD PRS results
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2027-08-15 |
| Phase | NA |
What NCT07087431 shows while recruiting
NCT07087431 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,285-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Immediate disclosure of CAD PRS results is the first listed.
NCT07087431 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07087431 about?
NCT07087431 is a clinical study titled "Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health". The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not cur...
What is the current status of trial NCT07087431?
This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2025-10-15. Estimated completion is 2027-08-15.
What conditions does trial NCT07087431 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT07087431?
The interventions under investigation include: Immediate disclosure of CAD PRS results (BEHAVIORAL), Deferred Disclosure of CAD PRS results (BEHAVIORAL).
Who is sponsoring clinical trial NCT07087431?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07087431 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07087431's enrollment target sits among peer trials
500 74th of 219 higher than 145 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment
RECRUITING · NA
-
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI